Accordingly, rebalancing of H3K27me3 levels at specific genes through EZH2 inhibitors has been proposed as a therapeutic strategy in cases of multiple myeloma and urothelial bladder carcinomas harboring KDM6A/UTX mutations [93, 94]. The gene discussed is KDM6A; the disease is plasma cell myeloma.